Amylin has filed a suit in the U.S. District Court for the Southern District of California charging that Eli Lilly violated an agreement over marketing of their joint diabetes drug Byetta. The company
says Eli Lilly has partnered with another drug company to marketing a competing diabetes drug.
The suite accuses Eli Lilly of violating federal laws and engaging in anti-competitive
practices by partnering with Boehringer Ingelheim on developing and marketing competitive drug Tradjenta.
Read the whole story at AboutLawsuits.com »